Abstract:Alzheimer's disease (AD) is the most common cause of dementia worldwide. Due to its uncertain pathogenesis, there is currently no treatment available for AD. Increasing evidences have linked cellular senescence to AD, although the mechanism triggering cellular senescence in AD requires further exploration. To investigate the involvement of cellular senescence in AD, we explored the effects of cadmium chloride (CdCl2) exposure, one of the potential environmental risk factors for AD, on neuron senescence in vivo and in vitro. β-amyloid (Aβ) and tubulin-associated protein (tau) pathologies were found to be enhanced by CdCl2 exposure in the in vitro models, while p53/p21/Rb cascade-related neuronal senescence pathways were activated. Conversely, the use of melatonin, a cellular senescence inhibitor, or a cadmium ion chelator suppressed CdCl2-induced neuron senescence, along with the Aβ and tau pathologies. Mechanistically, CdCl2 exposure activated the suppressor enhancer Lin-12/Notch 1-like (SEL1L)/HMG-CoA reductase degradation 1 (HRD1)-regulated endoplasmic reticulum-associated degradation (ERAD), which enhanced the ubiquitin degradation of sigma-1 receptor (SigmaR1) by specifically recognizing its K142 site, resulting in the activation of the p53/p21/Rb pathway via the induction of Ca2+ dyshomeostasis and mitochondrial dysfunction. In the in vivo models, the administration of the SigmaR1 agonist ANAVEX2-73 rescues neurobehavioral inhibition and alleviates cellular senescence and AD-like pathology in the brain tissue of CdCl2-exposed mice. Consequently, the present study revealed a novel senescence-associated regulatory route for the SEL1L/HRD1/SigmaR1 axis that affects the pathological progression of CdCl2 exposure-associated AD. CdCl2 exposure activated SEL1L/HRD1-mediated ERAD and promoted the ubiquitinated degradation of SigmaR1, activating p53/p21/Rb pathway-regulated neuronal senescence. The results of the present study suggest that SigmaR1 may function as a neuroprotective biomarker of neuronal senescence, and pharmacological activation of SigmaR1 could be a promising intervention strategy for AD therapy.

CDT2‐controlled Cell Cycle Reentry Regulates the Pathogenesis of Alzheimer's Disease

CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease.

The Role Of Cd2ap In The Pathogenesis Of Alzheimer'S Disease

TYK2 as a novel therapeutic target in Alzheimer Disease

DLK-MAPK Signaling Coupled with DNA Damage Promotes Intrinsic Neurotoxicity Associated with Non-Mutated Tau

TYK2 as a novel therapeutic target in Alzheimer's Disease with TDP-43 inclusions

The Role of Cdk5 in Alzheimer’s Disease

Tl-2 Attenuates Beta-Amyloid Induced Neuronal Apoptosis Through The Akt/Gsk-3 Beta/Beta-Catenin Pathway

Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction

The involvement of SigmaR1K142 degradation mediated by ERAD in neural senescence linked with CdCl2 exposure

A cell autonomous regulator of neuronal excitability modulates tau in Alzheimer's disease vulnerable neurons

CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer's Disease

Chk1 Inhibition Ameliorates Alzheimer’s Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling

E2F1 Mediates Traumatic Brain Injury and Regulates BDNF-AS to Promote the Progression of Alzheimer's Disease

Novel Insights Into DLAT's Role in Alzheimer's Disease‐Related Copper Toxicity Through Microglial Exosome Dynamics

Temporal manipulation of Cdkl5 reveals essential postdevelopmental functions and reversible CDKL5 deficiency disorder–related deficits

TREML2 Mutation Mediate Alzheimer’s Disease Risk by Altering Neuronal Degeneration

Unraveling the Molecular Dance: Insights into TREM2/DAP12 Complex Formation in Alzheimer's Disease through Molecular Dynamics Simulations

Molecular Networks and Key Regulators of the Dysregulated Neuronal System in Alzheimer’s Disease

Alzheimer's Disease Susceptibility Locus in CD2AP is Associated with Increased Cerebrospinal Fluid Tau Levels in Mild Cognitive Impairment.